{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:48:52Z","timestamp":1770277732681,"version":"3.49.0"},"reference-count":36,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\/Objectives: Minimal residual disease (MRD) refers to the resistant clonal population of leukemia cells that survive induction chemotherapy, serving as a critical indicator of treatment response in pediatric Acute Lymphoid Leukemia (ALL). While flow cytometry (FCM) and molecular methods are standard for MRD detection, novel leukemia-associated immunophenotype (LAIP) markers are needed when conventional markers are insufficient. Methods: MRD was assessed in 218 pediatric B-ALL patients using a combinatory approach of Different-from-Normal (DfN) and LAIP strategies. An eight-color flow cytometry panel included routine MRD markers (e.g., CD10, CD19, and CD20) and less commonly used markers (e.g., CD123, CD73, CD86). Cytogenetic and molecular profiling were integrated to evaluate the association between genetic abnormalities and MRD positivity. Results: The combined DfN and LAIP approach enhanced MRD detection sensitivity compared to individual methods. CD7 showed a significant association with MRD positivity (p = 0.003), whereas CD73 (p = 0.000) and CD86 (p = 0.002) correlated with MRD-negative status. CD123 exhibited the highest aberrancy among MRD-positive cases, while CD81 had the lowest. These findings highlight the prognostic potential of CD73 and CD86 for MRD-negative status, complementing the established utility of CD123. Conclusions: Incorporating novel markers (CD123, CD73, CD86, and CD81) into MRD panels enhances detection sensitivity and clinical applicability. These markers are compatible with standard flow cytometry, supporting their integration into routine practice for comprehensive MRD evaluation, ultimately improving therapeutic outcomes in pediatric B-ALL.<\/jats:p>","DOI":"10.3390\/diagnostics15060658","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T09:36:24Z","timestamp":1741599384000},"page":"658","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combinatory Flowcytometric Approach in Pediatric Acute Lymphoid Leukemia Identifies Surrogate Minimal Residual Disease Markers"],"prefix":"10.3390","volume":"15","author":[{"given":"Noreen Grace","family":"George","sequence":"first","affiliation":[{"name":"ICMR-National Institute of Child Health and Development Research (Formerly ICMR-National Institute of Pathology), New Delhi 110029, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5367-6050","authenticated-orcid":false,"given":"Bhavika","family":"Rishi","sequence":"additional","affiliation":[{"name":"ICMR-National Institute of Child Health and Development Research (Formerly ICMR-National Institute of Pathology), New Delhi 110029, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanghmitra","family":"Ray","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi 110029, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manpreet","family":"Kaur","sequence":"additional","affiliation":[{"name":"ICMR-National Institute of Child Health and Development Research (Formerly ICMR-National Institute of Pathology), New Delhi 110029, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj","family":"Kamal","sequence":"additional","affiliation":[{"name":"ICMR-National Institute of Child Health and Development Research (Formerly ICMR-National Institute of Pathology), New Delhi 110029, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikha","family":"Garg","sequence":"additional","affiliation":[{"name":"Dr. Dangs Lab, New Delhi 110016, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-8773","authenticated-orcid":false,"given":"Sumit","family":"Mehndiratta","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi 110029, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Chopra","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi 110029, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9446-767X","authenticated-orcid":false,"given":"Shamsuz","family":"Zaman","sequence":"additional","affiliation":[{"name":"ICMR-National Institute of Cancer Prevention, Noida 201301, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4440-5339","authenticated-orcid":false,"given":"Amitabh","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi 110029, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2884-3600","authenticated-orcid":false,"given":"Aroonima","family":"Misra","sequence":"additional","affiliation":[{"name":"ICMR-National Institute of Child Health and Development Research (Formerly ICMR-National Institute of Pathology), New Delhi 110029, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1182\/blood.V99.12.4386","article-title":"Detection of Minimal Residual Disease Identifies Differences in Treatment Response between T-All and Precursor B-All","volume":"99","author":"Willemse","year":"2002","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(94)90988-1","article-title":"Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction","volume":"343","author":"Brisco","year":"1994","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phoj.2020.12.003","article-title":"Minimal Residual Disease (MRD) detection in B- ALL\u2014Experience of a standalone flow cytometry laboratory","volume":"6","author":"Seth","year":"2021","journal-title":"Pediatr. Hematol. Oncol. J."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Dix, C., Lo, T.H., Clark, G., and Abadir, E. (2020). Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061714"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"620","DOI":"10.4103\/0973-1482.147716","article-title":"Characterization of immunophenotypic aberrancies in adult and childhood acute lymphoblastic leukemia: A study from Northern India","volume":"12","author":"Sharma","year":"2016","journal-title":"J. Cancer Res. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/ijlh.12716","article-title":"Immunophenotypic aberrancies in acute lymphoblastic leukemia from 282 Iraqi patients","volume":"39","author":"Jalal","year":"2017","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1182\/blood.V114.22.4119.4119","article-title":"CD22 Expression in Pediatric B-Lineage Acute Lymphoblastic Leukemia","volume":"114","author":"Jegalian","year":"2009","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12288-019-01228-0","article-title":"Flow Cytometry Based MRD and Its Impact on Survival Outcome in Children and Young Adults with ALL: A Prospective Study from a Tertiary Cancer Centre in Southern India","volume":"36","author":"Panda","year":"2020","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ratti, S., Lonetti, A., Follo, M.Y., Paganelli, F., Martelli, A.M., Chiarini, F., and Evangelisti, C. (2020). B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?. Cancers, 12.","DOI":"10.3390\/cancers12123498"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6279","DOI":"10.1182\/blood-2022-169696","article-title":"AML MRD By Multiparameter Flow Cytometry Using Laip\/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network","volume":"140","author":"Plesa","year":"2022","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1007\/s00277-021-04580-2","article-title":"Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL","volume":"100","author":"Das","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/2072-8069.194402","article-title":"Expression of CD10, CD13, CD19, CD20, CD22, CD33, CD34 and CD45 on B Lymphoblasts in Bone Marrow Aspirate of Adult Patients with Newly Diagnosed Acute Lymphoblasticleukemia Using Multicolor Flow Cytometry","volume":"3","year":"2014","journal-title":"Iraqi J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4103\/0973-1482.110378","article-title":"Correlation of morphologic and cytochemical diagnosis with flowcytometric analysis in acute leukemia","volume":"9","author":"Belurkar","year":"2013","journal-title":"J. Cancer Res. Ther."},{"key":"ref_14","unstructured":"Mourad, A. (2019). B-Cell Precursors: Immunophenotypic Features in the Detection of Minimal Residual Disease in Acute Leukemia. Normal and Malignant B-Cell, IntechOpen."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/cyto.b.21939","article-title":"Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion","volume":"100","author":"Tembhare","year":"2021","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_16","first-page":"241","article-title":"Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: Detection in remission marrow predicts outcome","volume":"105","author":"Griesinger","year":"1999","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/cyto.b.21101","article-title":"Detection of minimal residual disease in pediatric acute lymphoblastic leukemia","volume":"84","author":"Gaipa","year":"2013","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1182\/blood-2010-12-324004","article-title":"New markers for minimal residual disease detection in acute lymphoblastic leukemia","volume":"117","author":"Song","year":"2011","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5114\/ceji.2022.114530","article-title":"Expression of CD73 on leukemic blasts increases during follow-up\u2014A promising candidate marker for minimal residual disease detection in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"47","author":"Kulis","year":"2022","journal-title":"Cent.-Eur. J. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/cyto.b.21486","article-title":"Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000","volume":"94","author":"Tembhare","year":"2018","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1182\/blood-2009-10-247585","article-title":"CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia","volume":"115","author":"Rhein","year":"2010","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1751-553X.2010.01254.x","article-title":"CD66c expression in B-cell acute lymphoblastic leukemia: Strength and weakness","volume":"33","author":"Guillaume","year":"2011","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/cyto.b.21966","article-title":"Clinical and laboratory features associated with myeloperoxidase expression in pediatric B-lymphoblastic leukemia","volume":"100","author":"McGinnis","year":"2021","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21608\/ejhbmt.2024.382578","article-title":"Prognostic significance of tetraspanin (CD81) expression in patients with acute lymphoblastic leukemia","volume":"11","author":"Thabet","year":"2024","journal-title":"Egypt. J. Hematol. Bone Marrow Transplant."},{"key":"ref_25","first-page":"1245","article-title":"Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: Implications for the detection of minimal residual disease in acute lymphocytic leukemia","volume":"88","author":"Veltroni","year":"2003","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/lymphatics1020007","article-title":"Diagnosis and Molecular Pathology of Lymphoblastic Leukemias and Lymphomas in the Era of Genomics and Precision Medicine: Historical Evolution and Current Concepts\u2014Part 1: Lymphoid Neoplasms","volume":"1","author":"Kansal","year":"2023","journal-title":"Lymphatics"},{"key":"ref_27","first-page":"1839","article-title":"Prognostic value of peripheral blood blast percentage on day 8 in long term cure in patients with ALL","volume":"3","author":"Vaghela","year":"2014","journal-title":"World J. Pharm. Pharm. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-4598-9-41","article-title":"Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemia","volume":"9","author":"Rogers","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1055\/s-0042-1754337","article-title":"Cytogenetics and Molecular Genetics in Pediatric Acute Lymphoblastic Leukemia (ALL) and Its Correlation with Induction Outcomes","volume":"11","author":"Loganathan","year":"2022","journal-title":"South Asian J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/pbc.22944","article-title":"Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children\u2019s Oncology Group trial P9906","volume":"57","author":"Bowman","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_31","first-page":"458","article-title":"Systematic review of epigenetic targets in acute myeloid leukemia","volume":"11","author":"Verma","year":"2021","journal-title":"Am. J. Blood Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.hoc.2009.07.001","article-title":"Cytogenetics and molecular genetics of acute lymphoblastic leukemia","volume":"23","author":"Harper","year":"2009","journal-title":"Hematol. \/Oncol. Clin. N. Am."},{"key":"ref_33","first-page":"1747-0862","article-title":"Cytogenetics, Molecular Genetics and Epigenetics and Their Impact on The Management of Acute Lymphoblastic Leukemia","volume":"11","author":"Dridi","year":"2017","journal-title":"J. Mol. Genet. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kruse, A., Abdel-Azim, N., Kim, H.N., Ruan, Y., Phan, V., Ogana, H., Wang, W., Lee, R., Gang, E.J., and Khazal, S. (2020). Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21031054"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11912-012-0247-7","article-title":"Philadelphia-positive acute lymphoblastic leukemia: Current treatment options","volume":"14","author":"Kantarjian","year":"2012","journal-title":"Curr. Oncol. Rep."},{"key":"ref_36","unstructured":"Margarita, G., and Gueorgui, B. (2013). Genetics of Acute Lymphoblastic Leukemia. Leukemia, IntechOpen."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/6\/658\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:49:30Z","timestamp":1760028570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/6\/658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["diagnostics15060658"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15060658","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]}}}